CARL Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 19.97%, SMA50 14.99%, SMA200 10.0%). The stock’s 14-day RSI is 65.95 (firm momentum), while the ATR of 0.96 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -15.3% below its high and over 36.71% above its low. Average 10-day trading volume of 91.95 thousand shares is below the 3-month average of 143.71 thousand, indicating normal recent market interest.

Carlsmed, Inc. has 27.30 million shares outstanding. The public float is 15.67 million shares, elevated short interest at 13.50% of float. This equals 1.38 million shares. The short ratio is 9.58 days. Institutional investors hold 71.97% of the float. Insiders own 43.73%.

Wall Street analysts project EPS growth of 19.08% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $24.00 to $17.00. The high target offers 54.04% upside. The low target suggests 9.11% downside. The mean target is $20.43. This offers 31.13% upside. Carlsmed, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended August 05, 2026, missed forecasts by -1.52%. The prior quarter beat by -25.58%. Over the last six quarters, Apple has recorded several small beats. These include -3.29% in August 28, 2025.

currently trading near 52-week highs band. Valuation shows Carlsmed, Inc. trading at a premium to the broader market with a P/E of -11.49. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.80, suggesting 27.09% upside. Our AI forecast model points to short-term weakness (-6.68% over two weeks), a medium-term fall (-10.85% over three months), and a longer-term loss (-8.47% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Carlsmed, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.68%, with price expected at $14.54 by October 02, 2026, within a range of $13.93 to $15.12 3-Month Outlook: Projected fall of -10.85%, reaching $13.89 by December 17, 2026, with a range of $13.61 to $14.20. 1-Year Outlook: Projected loss of -8.47%, with price at $14.26 by September 17, 2027, within a range of $13.59 to $14.71.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Carlsmed, Inc. (NASDAQ:CARL) closed at $15.58 USD, gaining $0.19 (1.23%) from the previous close of $15.39. The stock is currently mid-range between its 52-week high and low $8.50 and $17.23. With a market capitalization of about $423.54 million, Carlsmed, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.94). Key stats such as the average daily volume over the past year has been around 142.30 thousand shares, trading with heavier-than-usual volume. Headquartered in Carlsbad, CA, Carlsmed, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Michael Cordonnier, the company employs approximately 127 people and listed since July 23, 2025. Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions.

Carlsmed, Inc. trades at a P/E ratio of -11.49, slightly below the S&P 500 average, with a price-to-sales ratio of 6.71 and a price-to-book ratio of 5.04 trading at moderately above to book value. The P/FCF stands at -12.42, also below market averages.